2023 Asco Annual Meeting News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from 2023 asco annual meeting. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In 2023 Asco Annual Meeting Today - Breaking & Trending Today

Retrospective Data Show Aggressive Axillary Surgery Is Not Associated With Improved Outcomes in Select Patients With Breast Cancer

Raymond Mailhot Vega, MD, MPH, delves into the rationale for exploring the outcomes of patients who underwent axillary surgery or sentinel lymph node biopsy, explained the implications of these findings, and detailed what eventual data from the phase 3 Alliance A011202 could mean for the breast cancer treatment paradigm. ....

Raymond Mailhot Vega , University Of Florida College Medicine , Department Of Radiation Oncology , Mailhot Vega , Radiation Oncology , Florida College , Breast Cancer , 2023 Asco Annual Meeting ,

PROs Represent a Vital Aspect in Design of GI Cancer Clinical Trials

Pamela Kunz, MD, details key clinical trial updates across the gastrointestinal cancer arena presented during the 2023 ASCO Annual Meeting, including the phase 3 PROSPECT trial in locally advanced rectal cancer and the phase 3 IMbrave050 trial in patients with resected in hepatocellular carcinoma at high risk of recurrence. ....

United States , New Haven , Pamela Kunz , Yale School Of Medicine , National Cancer Institute , Yale Cancer Center , News Network , Medical Oncology , Gastrointestinal Cancers , Smilow Cancer Hospital , Yale School , New York Times , Thenew York Times , Yale Cancer Center , Gastrointestinal Cancer , Hepatocellular Carcinoma , 2023 Asco Annual Meeting ,

Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS. ....

Myelodysplastic Syndromes , Recent Updates , Evolving Treatment Paradigms , Data From , Myelodysplastic Syndromes Recent Updates , Treatment Evolution Myelodysplastic Syndromes , Mds Management , Asco 2023 , 2023 Asco Annual Meeting , American Society Of Clinical Oncology , Mds Symptoms , Mds Diagnosis , Mds Presentations , High Risk Mds , Low Risk Mds ,

Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS. ....

Myelodysplastic Syndromes , Recent Updates , Evolving Treatment Paradigms , Data From , Myelodysplastic Syndromes Recent Updates , Treatment Evolution Myelodysplastic Syndromes , Mds Management , Asco 2023 , 2023 Asco Annual Meeting , American Society Of Clinical Oncology , Mds Symptoms , Mds Diagnosis , Mds Presentations , High Risk Mds , Low Risk Mds ,

ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS. ....

Myelodysplastic Syndromes , Recent Updates , Evolving Treatment Paradigms , Myelodysplastic Syndromes Recent Updates , Treatment Evolution Myelodysplastic Syndromes , Mds Management , Asco 2023 , 2023 Asco Annual Meeting , American Society Of Clinical Oncology , Mds Symptoms , Mds Diagnosis , Mds Presentations , High Risk Mds , Low Risk Mds ,